iSpecimen Inc. (NASDAQ:ISPC) Short Interest Update

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 305,108 shares, an increase of 2,171.8% from the November 30th total of 13,430 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 364,222 shares, the days-to-cover ratio is presently 0.8 days. Based on an average daily trading volume, of 364,222 shares, the days-to-cover ratio is presently 0.8 days. Approximately 3.6% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of brokerages have recently commented on ISPC. Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research report on Wednesday, October 8th. Wall Street Zen raised iSpecimen to a “sell” rating in a report on Saturday, September 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen as of its most recent filing with the Securities and Exchange Commission (SEC). 13.62% of the stock is currently owned by institutional investors and hedge funds.

iSpecimen Trading Up 1.2%

NASDAQ:ISPC traded up $0.00 during trading hours on Wednesday, hitting $0.39. 265,996 shares of the stock traded hands, compared to its average volume of 2,109,863. The firm has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.93. The firm has a market cap of $3.76 million, a price-to-earnings ratio of -0.05 and a beta of 1.80. iSpecimen has a fifty-two week low of $0.36 and a fifty-two week high of $3.38.

iSpecimen (NASDAQ:ISPC) last issued its quarterly earnings results on Monday, November 17th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.80) by $3.32. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $3.33 million. iSpecimen had a negative return on equity of 531.78% and a negative net margin of 343.86%.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.